CAPOX	Capecitabine + oxaliplatin
CRS	Cytoreductive surgery
CSFR	Colony-stimulating factor 1 receptor
DCR	Disease control rate
ENETS	European Neuroendocrine Tumor Society
FGFR	Fibroblast growth factor receptor
FOLFOX	5-fluorouracil + oxaliplatin
G1	Grade 1
G2	Grade 2
G3	Grade 3
GEP	Gastro-entero-pancreatic
HR	Hazard Ratio
HIPEC	Hyperthermal intraperitoneal chemotherapy
LAR	Long-Acting Release
MANECs	Mixed adeno-neuroendocrine carcinomas
MGMT	O6-methylguanine DNA methyltransferase
MiNENs	Mixed neuroendocrine non-neuroendocrine neoplasms
mOS	Median overall survival
mPFS	Median progression-free survival
mTORC1	Mammalian target of rapamycin complex 1
NANETS	North American NeuroEndocrine Tumors Society
NECs	Neuroendocrine carcinomas
NENs	Neuroendocrine neoplasms
NETs	Neuroendocrine tumors
ORR	Objective response rate
PanNENs	Pancreatic neuroendocrine neoplasms
PanNETs	Pancreatic neuroendocrine tumors
PDGFR	Platelet-derived growth factor receptor
PRRT	Peptide receptor radionuclide therapy
SCLC	Small cell carcinoma
SSA	Somatostatin analogs
SSTRs	Somatostatin receptors
TEMCAP	Temodal + capecitabine
TKI	Tyrosine kinase inhibitor
TTP	Time to Tumor Progression
VEGFR	Vascular endothelial growth factor receptor
WHO	World Health Organization